Crystal engineering plays a crucial role in controlling the structure, morphology, and functional properties of crystalline materials across multiple disciplines, including pharmaceutical science. Among various particle engineering techniques, crystallo-co-agglomeration (CCA) has gained significant attention as an innovative method for tailoring the physicochemical and mechanical properties of crystalline drug substances. By combining crystallization and agglomeration in a single process, CCA enables the formation of spherical crystalline agglomerates with improved particle size distribution, flowability, and compressibility.

The technique typically employs a ternary solvent system consisting of a good solvent, an anti-solvent, and a bridging liquid that promotes crystal agglomeration during nucleation and growth. Through careful control of process parameters such as solvent composition, agitation intensity, temperature, and bridging liquid concentration, the morphology and internal structure of crystalline agglomerates can be precisely engineered. This approach enables the production of functional crystalline particles with enhanced downstream processing characteristics.

From a crystal engineering perspective, CCA offers unique opportunities to manipulate crystal habit, surface properties, and interparticle interactions. The method also allows the incorporation of excipients or secondary components to produce composite crystalline materials with tailored dissolution and mechanical behavior. Recent studies have further demonstrated the potential of integrating advanced analytical techniques and computational tools to understand and optimize agglomeration mechanisms. Consequently, CCA provides an effective strategy for designing advanced crystalline pharmaceutical materials while contributing to broader developments in crystal engineering and materials science.